These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9579717)

  • 1. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.
    Salvarezza CR; Mingrone H; Fachinelli H; Kijanczuk S
    J Antimicrob Chemother; 1998 Mar; 41 Suppl B():75-80. PubMed ID: 9579717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections.
    Neu HC; Chick TW
    Chest; 1993 Nov; 104(5):1393-9. PubMed ID: 8222794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections.
    Laurent K
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():115-24. PubMed ID: 8818852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
    Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
    Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and ambulatory treatment of patients with community-acquired pneumonia: variability of complementary tests and study of the effectiveness of roxithromycin. Study Group on Ambulatory Treatment of Community-Acquired Pneumonia (NACTA)].
    Rev Clin Esp; 1999 Nov; 199(11):700-4. PubMed ID: 10638232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials.
    Quintiliani R
    Clin Ther; 1996; 18(3):373-90; discussion 372. PubMed ID: 8829015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. The Italian Multicentre Community-Acquired Pneumonia Group.
    De Palma M; Rocchi D; Canepa G; Peri A; Cantone V
    Clin Ther; 1995; 17(3):413-24. PubMed ID: 7585845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia.
    Poirier R
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():109-16. PubMed ID: 1827096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of cefixime and cefaclor in the treatment of acute otitis media in children.
    Piippo T; Stefansson S; Pitkäjärvi T; Lundberg C
    Scand J Infect Dis; 1991; 23(4):459-65. PubMed ID: 1957129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections.
    Müller O
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():83-92. PubMed ID: 8818849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.
    Ortqvist A; Valtonen M; Cars O; Wahl M; Saikku P; Jean C
    Chest; 1996 Dec; 110(6):1499-506. PubMed ID: 8989068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and tolerability of cefixime in the treatment of acute sinusitis.
    Gehanno P; Boucot I; Berche P; Uhlrich J
    Drugs; 1991; 42 Suppl 4():19-24. PubMed ID: 1725150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
    Kohno S; Tateda K; Mikamo H; Kadota J; Niki Y; Itamura R
    J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis.
    Chatzimanolis E; Marsan N; Lefatzis D; Pavlopoulos A
    J Antimicrob Chemother; 1998 Mar; 41 Suppl B():81-4. PubMed ID: 9579718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the clinical features of cefixime.
    Adam D
    Chemotherapy; 1998 Sep; 44 Suppl 1():1-5. PubMed ID: 9797415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
    Cazzola M; Vinciguerra A; Beghi GF; Paizis G; Giura R; Madonini V; Fiorentini F; Consigli GF; Tonna M; Casalini A
    J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of cefixime in the treatment of otitis media in infants and children.
    Bluestone CD
    Pediatr Infect Dis J; 1993 Jan; 12(1):75-82. PubMed ID: 8417430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.